SMARCA4 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4)
| Gene Symbol | SMARCA4 |
| HGNC ID | 11100 |
| Entrez ID | 6597 |
| Ensembl | ENSG00000127616 |
| Chromosome | 19p13.2 |
| Gene Type | Protein-coding |
| Protein | BRG1 protein |
| Key Domains | QLQ, HSA, BRK, DEXDc, HELICc, Bromodomain |
| Function | ATP-dependent chromatin remodeling ATPase |
| Disease Associations | Alzheimer's disease, Coffin-Siris syndrome type 4, rhabdoid tumors, Parkinson's disease |
SMARCA4 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
SMARCA4, also known as BRG1 (Brahma-Related Gene 1), encodes the catalytic ATPase subunit of the BAF, PBAF, and ncBAF chromatin remodeling complexes. SMARCA4 uses the energy of ATP hydrolysis to mobilize nucleosomes, creating accessible chromatin at gene regulatory elements.[1] In the nervous system, SMARCA4 is the predominant SWI/SNF ATPase in postmitotic neurons, where it is essential for activity-dependent gene expression, synaptic plasticity, and neuronal survival. Dysfunction of SMARCA4 is linked to Alzheimer's disease through impaired chromatin remodeling at neuroprotective gene loci and disruption of the neuronal epigenetic landscape.
The SMARCA4 gene spans approximately 80 kb on chromosome 19p13.2 and contains 35 exons encoding a 1647-amino acid protein. SMARCA4 is broadly expressed across all human tissues. In the brain, expression is highest in the cerebral cortex, hippocampus, and cerebellum. During neural development, a critical switch occurs from SMARCA2 (BRM) to SMARCA4 (BRG1) as neural progenitors exit the cell cycle and differentiate into postmitotic neurons.
Single-cell RNA sequencing of adult human brain tissue reveals SMARCA4 expression in all neuronal and glial cell types, with the highest levels in excitatory neurons and oligodendrocytes. In the aging brain, SMARCA4 expression declines selectively in hippocampal CA1 pyramidal neurons and entorhinal cortex neurons — the cell populations most vulnerable to Alzheimer's disease.[2]
SMARCA4/BRG1 is the catalytic engine of three distinct SWI/SNF complexes:
The ATPase domain of SMARCA4 belongs to the SNF2/SWI2 helicase superfamily and catalyzes three modes of nucleosome remodeling:
In neurons, SMARCA4 is recruited to activity-dependent enhancers and promoters by transcription factors such as CREB, MEF2, and AP-1, enabling rapid transcriptional responses to neuronal stimulation. This is critical for:
SMARCA4 dysfunction contributes to AD pathogenesis through multiple mechanisms:
Impaired activity-dependent transcription: Reduced SMARCA4 levels in AD hippocampal neurons compromise activity-dependent chromatin remodeling at enhancers of synaptic plasticity genes (ARC, BDNF, FOS), contributing to synaptic dysfunction and memory impairment.[4]
Amyloid-beta toxicity: Exposure to oligomeric amyloid-beta reduces SMARCA4 nuclear levels through proteasomal degradation, creating a chromatin accessibility deficit at neuroprotective gene loci. This represents an early event in AD pathogenesis preceding overt neurodegeneration.[2:1][5]
Tau-mediated nuclear dysfunction: Pathological tau disrupts nuclear architecture and SMARCA4 localization, contributing to the epigenetic dysregulation observed in tauopathies.[2:2]
Neuroinflammation: In microglia, SMARCA4-BAF complexes regulate the transition between homeostatic and disease-associated states. Loss of SMARCA4 function promotes a chronic pro-inflammatory microglial phenotype.[5:1]
DNA damage accumulation: SMARCA4 facilitates DNA double-strand break repair through nucleosome remodeling at damage sites. Reduced SMARCA4 activity leads to accumulation of DNA damage in aging neurons, a hallmark of AD.[2:3][5:2]
SMARCA4 maintains expression of dopaminergic neuron identity genes, including TH, DDC, and NURR1. Reduced SMARCA4 activity in substantia nigra neurons may contribute to dopaminergic neurodegeneration in Parkinson's disease.[6]
Heterozygous missense mutations in SMARCA4 (typically in the ATPase domain) cause Coffin-Siris syndrome type 4, confirming the dosage sensitivity of SMARCA4 in neural development.[7]
| Variant | Type | Association | Reference |
|---|---|---|---|
| ATPase domain missense | Dominant negative | Coffin-Siris syndrome type 4 | Tsurusaki et al., 2012 |
| rs12611091 | Intronic | Cognitive performance (GWAS) | Davies et al., 2018 |
| Reduced expression | Epigenetic | AD brain tissue | Nativio et al., 2018 |
Mashtalir et al. Modular organization and assembly of SWI/SNF family chromatin remodeling complexes (2018). 2018. ↩︎ ↩︎
Nativio et al. Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease (2018). 2018. ↩︎ ↩︎ ↩︎ ↩︎
Lessard et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development (2007). 2007. ↩︎
Vogel-Ciernia et al. The neuron-specific chromatin regulatory subunit BAF53b is necessary for synaptic plasticity and memory (2013). 2013. ↩︎
Gjoneska et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease (2015). 2015. ↩︎ ↩︎ ↩︎
Sokpor et al. Chromatin remodeling BAF complex subunit alterations in neural development (2017). 2017. ↩︎
Tsurusaki et al. Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome (2012). 2012. ↩︎